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Abstract
Background. Platelet-derived growth factor (PDGF) is
a central mediator of mesangioproliferative glomeru-
lonephritis (GN). In experimental mesangioproliferative
GN, PDGF-DD serum levels, unlike PDGF-BB, increased
up to 1000-fold.
Methods. We assessed disease activity in 72 patients with
GN, established a novel PDGF-D ELISA and then deter-
mined their PDGF-DD levels. In parallel, we studied renal
PDGF-DD mRNA expression by RT-PCR.
Results. PDGF-DD serum levels in patients with IgA
nephropathy (IgAN) were significantly higher (1.67 ±
0.45 ng/ml) and in patients with lupus nephritis signif-
icantly lower (0.66 ± 0.86 ng/ml) compared to healthy
controls (1.17 ± 0.46 ng/ml), while patients with focal seg-
mental glomerulosclerosis, membranous GN and ANCA-
positive vasculitis did not differ from controls. The sub-
group of IgAN patients with elevated PDGF-DD levels
(27% of samples) did not differ in their clinical features
from those with normal PDGF-DD levels. In IgAN patients
with repetitive PDGF-DD determinations, most exhibited
only minor fluctuations of serum levels over time. Intrarenal
PDGF-DD mRNA expression did not differ between con-
trols and patients, suggesting an extrarenal source of the
elevated PDGF-DD in IgAN.
Conclusions. Serum PDGF-DD levels were specifically
elevated in patients with IgAN, in particular in those with
early disease, i.e. preserved renal function. Our data support
the rationale for anti-PDGF-DD therapy in mesangioprolif-
erative GN.
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Introduction
Ample evidence links members of the platelet-derived
growth factor (PDGF) family to the pathogenesis of re-
nal diseases, in particular mesangioproliferative glomeru-
lonephritis (GN) (reviewed in [1]). PDGF-DD, like PDGF-
BB, is a major mitogen for mesangial cells that largely
signals through the PDGF receptor (PDGFR)-β [1] and is
crucially involved in the development of mesangioprolif-
erative GN. PDGF-DD, which is not normally expressed
in glomeruli, was prominently overexpressed in the mesan-
gial region following the induction of mesangioproliferative
anti-Thy 1.1 nephritis in rats [2]. In mice, hepatic viral over-
expression of a human PDGF-DD construct induced mesan-
gioproliferative changes [3]. Finally, in mesangioprolifer-
ative anti-Thy 1.1 nephritis glomerular cell proliferation,
matrix accumulation and subsequent glomerulosclerosis
and tubulointerstitial damage were all significantly re-
duced by a specific neutralizing anti-PDGF-DD mon-
oclonal antibody [2,4]. Similar findings had also pre-
viously been described in the case of PDGF-BB [1].
However, whereas PDGF-BB exerts mostly autocrine and
paracrine short-range actions, we noted during the course
of experimental mesangioproliferative nephritis in rats that
PDGF-DD plasma levels increased ∼1000-fold [2]. Thus,
unlike PDGF-BB, PDGF-DD apparently also acts as an
endocrine growth factor [2,5] and might represent a non-
invasive marker for mesangioproliferative GN. This obser-
vation prompted us to investigate the PDGF-DD expression
in patients with renal diseases and in particular the ques-
tion of whether PDGF-DD serum levels in patients with
glomerular disease, especially mesangioproliferative IgA
nephropathy (IgAN), can serve as a biomarker of disease
and/or disease activity.
Subjects and methods
Patients and serum samples
Sample collection and the clinical study were approved by the lo-
cal Institutional Review Board and were performed according to the
Declaration of Helsinki. All serum samples and clinical parameters
were prospectively obtained during scheduled outpatient clinic vis-
its at the University Hospital Aachen. Once drawn, blood samples
C© The Author [2009]. Published by Oxford University Press on behalf of ERA-EDTA. All rights reserved.
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Table 1. Patient characteristics
Disease entity IgANa (n = 33) LN (n = 18) FSGS (n = 10) VAS (n = 8) MN (n = 12)
Serum PDGF-DD (ng/ml) 1.67 ± 0.45 0.66 ± 0.86 0.85 ± 0.36 1.12 ± 0.66 1.26 ± 0.64
1.70 (0.56–2.72) 0.28 (0.06–3.15) 0.87 (0.41–1.33) 0.88 (0.39–2.36) 1.25(0.27–2.68)
Age (years) 40 ± 13 45 ± 16 38 ± 14 59 ± 14 52 ± 16
39 (19–78) 44 (20–77) 38 (18–63) 60 (41–76) 46 (25–77)
Sex (male:female) 24: 9 4: 14 5: 5 7: 1 6: 6
Body weight (kg) 80 ± 18 73 ± 19 82 ± 17 87 ± 10 89 ± 27
83 (51–120) 70 (45–110) 81 (63–107) 91 (73–99) 84 (64–170)
BMI (kg/m2) 26 ± 5 25 ± 5 22 ± 19 28 ± 4 32 ± 11
25 (20–38) 24 (17–35) 25 (21–40) 28 (23–34) 30 (23–65)
SBP (mmHg) 138 ± 17 123 ± 13 133 ± 20 139 ± 25 142 ± 18
135 (109–170) 125 (100–140) 140 (90–160) 133 (115–180) 145 (115–170)
DBP (mmHg) 83 ± 11 74 ± 8 88 ± 13 80 ± 16 79 ± 14
80 (65–120) 75 (60–90) 88 (70–110) 85 (60–105) 78 (55–100)
No. of anti-hypertensive drugs 1.6 ± 1.0 1.3 ± 1.3 1.5 ± 1.0 1.5 ± 0.8 2.3 ± 1.4
1 (0–4) 1 (0–4) 1 (0–3) 1 (1–3) 2 (0–4)
Immunosuppression 6 (18%) 18 (100%) 3 (30%) 3 (38%) 5 (42%)
Serum creatinine (mg/dl) 2.0 ± 1.5 1.4 ± 0.9 1.5 ± 0.5 1.9 ± 0.6 1.9 ± 1.0
1.5 (0.8–8.4) 1.1 (0.7–4.5) 1.5 (0.8–2.2) 1.8 (1.2–3.2) 1.5 (0.9–3.5)
Serum total protein (g/l) 68 ± 7 67 ± 10 59 ± 12 67 ± 5 55 ± 10
68 (52–86) 68 (42–80) 63 (41–73) 69 (56–73) 57 (40–70)
Serum CRP (mg/l) 4 ± 8 5 ± 6 2 ± 4 24 ± 39 3 ± 4
0 (0–43) 6 (0–16) 0 (0–10) 3 (0–88) 0 (0–11)
(G/l) 7.7 ± 2.1 8.5 ± 4.6 7.9 ± 2.2 7.8 ± 3.5 13.7 ± 20.1
7.5 (4.2–11.9) 6.9 (4.0–21.2) 7.6 (5.2–12.0) 6.0 (4.4–13.6) 7.4 (4.4–74.0)
Creatinine clearance (ml/min) 71 ± 39 72 ± 47 57 ± 40 65 ± 35 79 ± 48
72 (20–195) 54 (13–156) 45 (17–124) 59 (29–129) 80 (12–157)
24-h proteinuria (g/day) 2.5 ± 2.6 1.1 ± 1.4 3.2 ± 2.1 1.1 ± 0.7 5.6 ± 6.4
2.3 (0–9.8) 0.4 (0–4.1) 3.0 (0.2–6.4) 0.9 (0.4–2.1) 2.2 (0–19.1)
U-protein to creatinine (mg/g × 103) 2.4 ± 2.1 5.6 ± 7.5 2.9 ± 2.1 0.8 ± 0.5 9.5 ± 6.4
1.9 (0.2–6.7) 5.6 (0.3–10.8) 3.5 (0.2–6.5) 0.8 (0.4–1.6) 10.6 (0.9–16.3)
U-albumin to U-creatinine (mg/g × 103) 1.9 ± 1.6 3.9 ± 5.5 2.3 ± 1.6 0.6 ± 0.5 5.7 ± 4.2
1.5 (0.1–5.2) 3.9 (0.1–7.7) 2.3 (0.1–4.8) 0.4 (0.2–1.4) 6.1 (0.7–10.2)
LDH (U/l) 173 ± 35 228 ± 62 213 ± 61 213 ± 95 247 ± 107
166 (123–271) 205 (131–354) 193 (157–352) 182 (137–429) 218 (147–517)
Haematuria—none 23% 53% 70% 50% 40%
(+) 27% 27% 20% 12.5% 50%
+ 15% 20% 10% 12.5% 10%
++ 32% 0% 0% 25% 0%
+++ 3% 0% 0% 0% 0%
BMI, body mass index; SBP, systolic blood pressure; DBP, diastolic blood pressure.
aIn the case that IgAN patients’ PDGF-DD serum levels measured in the first available sample entered the table.
All values are means ± SD in the upper rows and median (minimum–maximum) in the lower rows or percent of patients.
were separated and sera were stored immediately at −80◦C until the
assay.
A total of 167 serum samples were obtained from patients with the
following biopsy-confirmed diagnoses: primary IgAN (137 samples from
33 patients with the follow-up from 0 to 52 months), focal segmental
glomerulosclerosis (FSGS; 10 samples from 10 patients), ANCA-positive
vasculitis (VAS; 8 samples from 8 patients) and membranous nephropa-
thy (MN; 12 samples from 12 patients). We also analysed 18 sera from
patients with lupus nephritis (LN), of which 9 had biopsy-proven LN
(1 patient with WHO class I, 2 patients with class II, 3 patients with class
IV and 2 patients with class VI), whereas the remaining 9 had suspected
nephritis due to lupus erythematosus and proteinuria. We excluded pa-
tients with secondary GN forms and active infections. At the time of each
outpatient visit, the parameters listed in Table 1 were assessed. Proteinuria
and creatinine clearance were measured based on 24-h urine collections.
Immunosuppression was defined as any type of immunosuppressive med-
ication at the time of obtaining the blood sample, i.e. corticosteroids,
cyclophosphamide, cyclosporine A, tacrolimus, azathioprine or combina-
tions thereof.
Forty-four healthy blood donors with a mean age of 38 ± 13 years
(median age 38, range 21–63 years), 26 men and 16 women, served
as normal controls (only age and sex were available for this group). It
has been previously shown that patients with lung cancer have elevated
serum PDGF-DD levels [6]. Therefore, we have analysed 18 samples from
patients with various types of lung cancer as a positive control for the
ELISA.
ELISA for PDGF-DD in human serum
A specific sandwich ELISA was developed to measure human serum
PDGF-DD. The antibodies used for the ELISA were provided by Curagen
Corp. (Branford, CT, USA). Briefly, the ELISA was performed as follows:
100 µl of capture antibody (fully human monoclonal anti-PDGF-DD Ab;
0.25 µg/ml) in a coating buffer [0.05 M NaHCO3 (pH 9.6)] was coated on
ELISA plates. After overnight incubation at 4◦C, the plates were washed
(four times) using 0.05% Tween 20 in PBS (washing buffer) and 225 µl
of blocking buffer (0.5% BSA, 0.1% Tween 20, 0.01% Thimerosal in
PBS) was added for 1 h at 25◦C. After washing, 100 µl of standards and
serum samples were added and plates were incubated at 37◦C for 1 h.
After washing again, 1-h incubation at 37◦C with 100 µl of detection
antibody followed (horseradish peroxidase-conjugated rabbit polyclonal
anti-human-PDGF-DD Ab; 0.3 µg/ml). After washing, the plates were
incubated for 10 min at room temperature in the dark with 100 µl of HRP
substrate (TMB reagent, R&D) and the reaction was stopped with 100 µl
of 1 N H2SO4. The plates were analysed on an ELISA plate reader at
450 nm with a correction at 570 nm. Serum PDGF-DD concentrations
were calculated from a PDGF-DD standard curve using a four-parameter
curve-fitting program. Detection and capture antibodies detected both
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latent and active PDGF-DD, i.e. PDGF-DD with and without CUB
domain, respectively (data not shown).
Western blot or PDGF-DD in human serum
PDGF-DD western blotting was performed in six healthy subjects and
eight IgAN patients as previously described with minor modifications
[2]. Briefly, sera were diluted in a SDS–PAGE sample buffer to obtain
equal protein content, and 20 µl were then subjected to 10% SDS–PAGE
under reducing conditions. Proteins were transferred to Hybond-P mem-
branes (Amersham), and filters were probed with affinity-purified rabbit
polyclonal anti-PDGF-DD Ab (kindly provided by Dr Eriksson, Ludwig
Institute for Cancer Research, Stockholm, Sweden) or control rabbit IgG
for 12 h. After washing, filters were incubated with an anti-rabbit HRP sec-
ondary antibody. Bands were visualized by enhanced chemiluminescence
(Amersham).
Microdissection, RNA isolation, real-time PCR analyses
Human kidney biopsies from healthy living kidney donors (LD; n= 9), pa-
tients with IgAN (n= 24), LN (n= 11), FSGS (n= 13), rapidly progressive
GN (RPGN; n = 9) or with MN (n = 22), were obtained in a multicentre
study for gene expression analysis in renal biopsies (see the Acknowl-
edgements for participating centres). Informed consent of the patients and
agreements of the local ethics committees were obtained. For a detailed
description of the protocol used see [7]. In brief, directly after biopsy a cor-
tical tissue segment was transferred into a commercially available RNase
inhibitor (RNAlater, Ambion, TX, USA), stored at −20◦C followed by
manual microdissection to separate glomeruli and tubulointerstitial com-
partments in RNAlater. Total RNA was isolated using a commercially
available silica-gel-based isolation protocol and underwent reverse tran-
scription. Real-time PCR (RT-PCR) was performed on an ABI PRISM
7700 Sequence Detection System (Applied Biosystems, Darmstadt, Ger-
many). Glomerular microdissection was confirmed by RT-PCR for the
glomerulus-specific cDNA for Wilms tumour antigen 1. A predeveloped,
cDNA-specific assay for PDGF-DD (Hs00937332_ml, Applied Biosys-
tems) was used, and the PDGF-DD mRNA expression was normalized to
two reference genes (GAPDH and 18S rRNA, both predeveloped assays
from Applied Biosystems). Both reference genes gave comparable results.
Water and no-template controls were negative in all runs.
Statistics
Data are given as means ± SD and median (minimum–maximum). Since
the Kolmogorov–Smirnov test indicated a non-normal distribution of the
data, we applied non-parametric tests (Kruskal–Wallis H-test and Mann–
Whitney U-test) to compare patient groups and Spearman’s correlation to
analyse the association between the tested variables. We used the χ2 test
to compare categorical variables. All tests were two-tailed, and statistical
significance was defined as P < 0.05.
Results
Characteristics of the PDGF-DD ELISA and circulating
PDGF-DD
The lower quantification limit of the PDGF-DD ELISA was
0.2 ng/ml. Intra- and inter-day precisions were assessed by
serial measurements, and in repetitive runs, yielded coef-
ficients of variation of 1.0–8.7% and 6.3–8.7%, respec-
tively. Recovery of PDGF-DD from naı¨ve serum was 94.1,
90.2 and 99.5% at 0.6, 5.0 and 40.0 ng/ml PDGF-DD, re-
spectively. Serum concentrations were stable within three
freeze-thaw cycles.
In healthy blood donors, PDGF-DD levels were 1.17 ±
0.46 ng/ml. The normal range was set as mean ± 2 SD:
0.25–2.09 ng/ml (Figure 1). The 5th and 95th percentiles
were similar at 0.43 and 2.01 ng/ml, respectively.
Fig. 1. Individual serum PDGF-DD concentrations in healthy subjects, in
patients with glomerular diseases and in patients with lung cancer. The hor-
izontal lines depict the mean values of the groups. The following groups are
shown: healthy controls (healthy), patients with IgA nephropathy (IgAN),
lupus nephritis (LN), focal segmental glomerulosclerosis (FSGS), ANCA-
positive vasculitis (VAS), membranous nephropathy (MN) and various
types of lung cancer (Lung Ca). The Kruskal–Wallis H-test indicated sig-
nificant differences (P< 0.001) between the groups. Differences between
groups were evaluated using the Mann–Whitney U-test.
Fig. 2. Representative PDGF-DD western Blot analysis under reducing
conditions with sera from four IgAN patients and three healthy con-
trols. The black arrows label specific bands that most likely represent
the monomer plus CUB domain (about 47 kD), the dimer form with-
out CUB domain (about 34 kD) and the monomer without CUB domain
(about 22 kD). IgAN patients and healthy controls exhibited no obvious
differences in molecular characteristics of their circulating PDGF-DD.
M = size marker, Neg = negative control (blot was incubated with irrele-
vant rabbit IgG instead of the specific rabbit anti-PDGF-D-Ab).
PDGF-DD levels were markedly elevated in patients
with lung cancer that were included as ‘positive’ controls
(Figure 1) [6].
To assess whether the molecular characteristics of circu-
lating PDGF-DD are altered in patients with renal disease,
we performed western blotting under reducing conditions
(Figure 2). We detected three specific bands of ∼47, 35
and 22 kD, most likely representing monomeric PDGF-DD
including its CUB domain (47 kD), the dimer form without
a CUB domain (34 kD) and the monomer without a CUB
domain (22 kD) [2,5]. Sera from patients and controls did
not differ. Furthermore, no differences were detected be-
tween IgAN patients with different serum creatinine and
PDGF-DD concentrations.
PDGF-DD levels in different glomerular diseases
The clinical characteristics of the patients are given in
Table 1. When compared with healthy subjects, serum
PDGF-DD concentrations were similar in patients with
FSGS, MN and VAS. Patients with IgAN and LN exhibited
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Fig. 3. Correlation between PDGF-DD serum levels and creatinine clearance, urinary protein or albumin to creatinine ratios, LDH and leukocytes in
the whole cohort and in patients with IgAN. Each graph shows the individual values, linear regression line (full line) and the 95% confidence interval
band of the regression line (dashed lines), Spearman correlation coefficient (R), statistical significance (p) and the number of subjects analysed (n).
Crea clearance = creatinine clearance; U-prot./U-crea. = urinary protein to creatinine ratio; U-alb./U-crea = urinary albumin to creatinine ratio.
significantly higher and lower concentrations, respectively,
than normal controls (Table 1 and Figure 1).
PDGF-DD serum levels were comparable in males and
females of the whole group and the subgroups of healthy
subjects and patients with LN, FSGS and MN (data not
shown). In contrast, male IgAN patients exhibited higher
serum PDGF-DD than females (1.76 ± 0.48 ng/ml, me-
dian 1.86, range 0.56–2.72 in 24 male patients versus
1.44 ± 0.25, 1.38 and 1.12–1.74 in 9 female patients, re-
spectively; P = 0.036).
As can be seen in Figure 1, all LN patients exhibited low
PDGF-DD serum levels apart from two patients, both of
whom had advanced sclerosing LN (class VI).
We detected no correlation between age and serum
PDGF-DD concentrations in the whole population or in
the disease subgroups.
Effects of proteinuria and renal function on PDGF-DD
serum levels
In the whole cohort of renal patients (including the follow-
up samples), serum PDGF-DD concentrations correlated
positively with creatinine clearance (P= 0.034) and leuko-
cyte counts (P = 0.001) and negatively with lactate dehy-
drogenase (LDH; P= 0.004), a non-specific marker of cell
damage (Figure 3). Urinary protein to urinary creatinine ra-
tios and urinary albumin to urinary creatinine ratios showed
a trend to be negatively correlated with serum PDGF-DD
levels, but the correlation failed to reach statistical signif-
icance (Figure 3). No other measured variables of renal
function correlated with PDGF-DD serum levels.
To extend these observations, we divided the cohort into
four groups according to 25th percentiles of PDGF-DD
concentrations (Table 2). In this analysis, creatinine clear-
ance was highest in the patient percentile with the highest
PDGF-DD serum concentrations. Notably, the patients in
the lowest PDGF-DD percentile also had a relatively high
clearance creatinine. A negative correlation of PDGF-DD
serum levels with LDH concentrations was confirmed in
this analysis. Leukocyte counts were significantly elevated
in the PDGF-DD group with the lowest values. Finally, by
χ2 testing the number of patients receiving immunosup-
pression was significantly higher in the 0–25th percentile
group (Table 2).
IgAN
In patients with IgAN (including the follow-up samples),
we found PDGF-DD to be significantly and positively
correlated with creatinine clearance and leukocyte counts
(Figure 3). These findings were uniformly confirmed after
categorization of IgAN patients into groups according to
PDGF-DD percentiles (Table 3).
When we separated the IgAN patients based on
PDGF-DD concentrations below or above the upper nor-
mal limit (see above), we confirmed the association
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Table 2. Division of the whole patient cohort into four groups based on 25th percentiles of serum PDGF-DD concentrations
Percentile 0–25th (n = 44) 25th–50th (n = 38) 50th–75th (n = 51) 75th–100th (n = 52) P-value
Serum PDGF-DD (ng/ml) <0.96 0.97–1.32 1.33–1.85 >1.86
Creatinine clearance (ml/min) 79 ± 48§§ 55 ± 38 72 ± 53 87 ± 54# 0.016
65 (16–169) 33 (20–156) 54 (4–208) 73 (13–219)
(G/l) 8.8 ± 10.6§,$,& 6.3 ± 2.2 6.8 ± 2.1 8.8 ± 2.7 <0.001
6.8 (4.0–74.0) 6.3 (3.2–12.0) 6.4 (4.1–11.9) 8.5 (5.0–16.5)
LDH (U/l) 204 ± 53§,$,& 177 ± 46 183 ± 59 179 ± 53 0.005
197 (123–354) 168 (123–352) 171 (123–517) 168 (120–429)
Immunosuppression∗ 8.4% 2.2% 3.1% 6.2% 0.006
P-values of Kruskal–Wallis H-tests for the numeric parameters or the χ2 test for immunosuppression are shown. The data are given as means ± SD in
the upper row and medians (minimum–maximum) in the lower row or as percentage of patients receiving immunosuppression.
∗All patients, except for three receiving cyclosporine A as monotherapy, were treated with corticosteroids as mono- or combination therapy.
The Mann–Whitney U-test was used to detect differences between individual groups.
0–25th versus 25th–50th: §P < 0.01 or §§P < 0.05; 0–25th versus 50th–75th: $P < 0.01 or $$P < 0.05; 0–25th versus 75th–100th: &P < 0.01;
75th–100th versus 25th–50th: #P < 0.01; 75th–100th versus 50th–75th: ∗P < 0.05.
Table 3. Division of IgA nephropathy patients into four groups according to 25th percentiles of serum PDGF-DD concentrations
Percentile 0–25th (n = 13) 25th–50th (n = 34) 50th–75th (n = 42) 75th–100th (n = 48) P-value
Serum PDGF-DD (ng/ml) < 0.96 0.97–1.32 1.33–1.85 >1.86
Creatinine clearance (ml/min) 91 ± 56 51 ± 33 72 ± 55 91 ± 53#,∗∗ 0.003
98 (16–169) 32 (20–118) 51 (4–208) 77 (14–219)
(G/l) 6.9 ± 1.6 6.1 ± 2.0 6.7 ± 2.0 8.4 ± 2.2&,#,∗ <0.001
6.8 (4.5–9.7) 6.0 (3.2–11.7) 6.2 (4.1–11.9) 8.4 (5.0–13.4)
Kruskal–Wallis H-test P-values are shown. The data are given as means ± SD in the upper rows and medians (minimum–maximum) in the lower rows.
The Mann–Whitney U-test was used to detect differences between individual groups.
0–25th versus 25th–50th: §P < 0.05; 75th–100th versus 0–25th: &P < 0.05; 75th–100th versus 25th–50th: #P < 0.01; 75th–100th versus 50th–75th:
∗P < 0.01 or ∗∗P < 0.05.
Table 4. IgA nephropathy patients; comparison of serum samples with
PDGF-DD concentrations above or below the upper limit of normal
Serum PDGF-DD
(ng/ml)
<2.01 >2.01 P-value
n 100 37
DBP (mmHg) 82 ± 9 75 ± 8 0.001
80 (60–120) 80 (60–95)
Creatinine clearance
(ml/min)
68 ± 48 97 ± 57 <0.005
53 (4–208) 86 (14–219)
(G/l) 6.7 ± 2.0 8.4 ± 2.3 <0.001
6.6 (3.2–13.0) 8.5 (5.0–13.4)
Proteinuria (g/day) 1.4 ± 2.0 1.6 ± 1.8 n.s.
0.7 (0–10.5) 1.0 (0–7.0)
Haematuria—none 44% 48% n.s.
+ 25% 16%
++ 16% 14%
+++ 15% 22%
Patients receiving
immunosuppressiona
8% 24% <0.05
(2 of 100) (9 of 37)
DBP, diastolic blood pressure; n.s. = not significant.
Mann–Whitney U-test P values are shown except for haematuria, which
was assessed by the χ2 test. The data are given as means ± SD in the
upper rows and medians (minimum–maximum) in the lower rows.
aAll patients receiving immunosuppression had corticosteroids as mono-
or combination therapy.
of high PDGF-DD concentrations with higher creati-
nine clearance and high leukocyte counts (Table 4).
In addition, high PDGF-DD levels were associated with
lower diastolic blood pressure and the administration of
immunosuppression (Table 4). In contrast, no significant
differences evolved for potential markers of disease activ-
ity, i.e. the extent of proteinuria or haematuria, in the two
groups (Table 4).
Attempts to detect PDGF-DD in urine samples of these
patients consistently failed (data not shown).
Individual course of PDGF-DD levels during the
follow-up in patients with IgAN
Multiple samples (median 4, range 1–16 samples per pa-
tient) were available in the majority of patients with IgAN
during 16 ± 18 months of follow-up. As shown in Figure 4,
in those patients for whom four or more samples were avail-
able, most patients exhibited relatively little fluctuation over
time and individual coefficients of variation were 21 ± 7%
(range 8–32%). Of note, the patient with the highest PDGF-
DD level in Figure 4, i.e. 3.68 ng/ml, had no evidence of
renal disease activity at the time of the serum sample (i.e.
normal creatinine clearance, proteinuria below 200 mg/day,
no haematuria, normal CRP) or at the time of the next sam-
ple, which was obtained 6 months later. During the follow-
up, the clinical features of these IgAN patients remained
stable in the majority of cases.
PDGF-DD serum levels in other disease entities
We failed to detect any association between PDGF-DD
serum levels and any of the measured parameters in pa-
tients with MN or VAS. In patients with FSGS, PDGF-DD
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Fig. 4. Individual courses of PDGF-DD serum levels in patients with
IgAN during 0–52 months of follow-up. Only those patients (n = 14)
for whom four or more serum samples were available for measurements
entered the graph.
was positively correlated with the urinary protein to creati-
nine ratio (R = 0.786, P = 0.036, n = 7), urinary albumin
to creatinine ratio (R = 0.762, P = 0.028, n = 8) as well
as LDH (R = 0.881, P = 0.004, n = 8). In patients with
LN, we found PDGF-DD to be negatively correlated with
serum total protein (R = −0.489, P = 0.040, n = 18)
and positively correlated with 24-h proteinuria (R = 0.587,
P = 0.035, n = 13) and haematuria (R = 0.597, P = 0.024,
n = 14).
Intrarenal expression of PDGF-DD mRNA
To investigate intrarenal synthesis of PDGF-DD at the
mRNA level, microdissected glomeruli and tubulointersti-
tium were examined. Compared to normal glomeruli ob-
tained from living kidney donors, we found no difference in
PDGF-DD mRNA expression in glomeruli of patients with
IgAN, LN, FSGS, MN or rapidly progressive GN (Figure 5).
We also found no alteration in tubulointerstitial PDGF-DD
transcript numbers in the same set of patients (Figure 5).
Discussion
To our knowledge, only two studies so far have reported on
PDGF-DD levels in humans. In the first study, 50 normal
controls mostly exhibited mean serum values of <4 ng/ml,
which was the sensitivity limit of the ELISA [6]. Only
three patients were reported to have PDGF-DD serum levels
>10 ng/ml [6]. Whereas such high values were not observed
in our normal population using a different ELISA, the nor-
mal range determined in the present study, i.e. 0.25–2.09 ng/
ml, is most compatible with these prior observations. In that
first study, patients with ovarian, renal, lung, breast and
brain cancer frequently exhibited serum PDGF-DD levels
>10 ng/ml [6], which was also confirmed in the present
study in patients with lung cancer and thus served as a pos-
itive control. A second study, published in Chinese, also
described increased serum and urinary PDGF-DD levels in
children with IgAN when compared to healthy controls [8].
In contrast to the present study, PDGF-DD was positively
correlated with proteinuria and was upregulated in renal
biopsies of IgAN children.
Fig. 5. Box-plots of intrarenal expression of PDGF-DD mRNA in pa-
tients with glomerular diseases. We found no significant differences in
the PDGF-DD mRNA expression in microdissected glomeruli or the
tubulointerstitium in healthy living kidney donors (LD; n = 9), pa-
tients with IgA nephropathy (IgAN; n = 24), lupus nephritis (LN;
n = 11), focal segmental glomerulosclerosis (FSGS; n = 13), rapidly
progressive glomerulonephritis (RPGN; n = 9) or with membranous
nephropathy (MN; n= 22). PDGF-DD mRNA data shown are normalized
to the reference gene GAPDH. Levels in healthy kidney donors were set
as 1. Outliers are marked with asterisks.
The major observation of the present study was that pa-
tients with IgAN exhibited raised serum concentrations of
PDGF-DD in ∼30% of the samples obtained. The increases
were generally mild and not comparable to the situation in
an experimental model of mesangioproliferative GN (anti-
Thy 1.1 nephritis), where at the peak of disease activity we
found PDGF-DD protein levels of 27.7 ± 14.5 ng /ml as
compared to the levels in normal rats. The latter were con-
sistently below the detection limit (<0.02 ng/ml) [2]. Apart
from species and assay differences, a likely explanation to
reconcile these data is that the anti-Thy 1.1 model is a fulmi-
nant and synchronized model of mesangioproliferative GN,
whereas the course of human mesangioproliferative IgAN
is much more variable and insidious. Our data emphasize
the caveats of extrapolating from experimental data to clini-
cal practice and urge for the development of animal models
that would more closely mimic the slow course of human
IgAN. Also, in the human disease, kinetics of disease ac-
tivity, e.g. chronic low-grade versus repetitive bouts, are
largely unknown since no reliable non-invasive laboratory
markers exist for its assessment. Importantly, both protein-
uria and microhaematuria may indicate both disease activ-
ity and glomerular defects following phases of activity. The
latter may explain why we failed to detect significant dif-
ferences in the extent of proteinuria and haematuria when
we compared samples with normal and elevated PDGF-
DD levels. The weak negative correlation between PDGF-
DD levels and proteinuria, which only became apparent
when all patients with glomerular diseases were pooled,
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most likely indicates urinary losses of PDGF-DD in heavy
proteinuria.
A second insight gained by our study is the positive corre-
lation of PDGF-DD serum levels with creatinine clearance
in both patients with IgAN and the whole patient pop-
ulation. In the whole population, this correlation largely
depended on the IgAN patients, since the statistical sig-
nificance of the correlation was lost when only the sera
of patients with non-IgAN diseases were assessed (data
not shown). The particularly notable feature, therefore,
is that unlike most other low-molecular-weight proteins,
PDGF-DD (molecular weights 22–47 kDa) did not appear
to accumulate in serum with advancing renal failure. In
contrast to PDGF-DD, serum levels of PDGF-AB (molec-
ular weight 28–35 kDa) increased ∼20–100% in advanced
renal failure [9,10]. Also, in contrast to PDGF-BB and -AB
[11], no association between increased PDGF-DD levels
and hypertension evolved in the present study.
A third observation of our study was the positive corre-
lation of PDGF-DD serum levels with leukocyte counts
in both whole renal disease population and in patients
with IgAN. While we are not aware of studies specifi-
cally investigating circulating leukocyte content of PDGF,
it was reported that PDGF-DD is expressed by synovial
macrophages of patients with rheumatoid arthritis and in
macrophages of atherosclerotic plaques [12,13]. In addi-
tion, PDGF-DD mRNA has been detected in peripheral
blood leukocytes [14]. Given the correlation of PDGF-DD
levels with leukocyte counts, these may play a role as origin
of PDGF-DD synthesis. Release of PDGF-DD by circulat-
ing leukocytes could also contribute to our observation that
patients with corticosteroid-induced leukocytosis exhibited
elevated PDGF-DD serum levels (Table 4).
Fourthly, we noted a dissociation of PDGF-DD serum
levels and intraglomerular PDGF-DD synthesis, in that
serum levels were elevated in IgAN patients and decreased
in LN patients, whereas intrarenal PDGF-DD mRNA con-
tent did not differ from that of healthy kidneys in either dis-
ease entity. In prior systematic studies, PDGF-DD mRNA
expression was high in adrenal glands, pancreas, adipose
tissue, mammary glands, testis and stomach [5]. Some-
what lower expression was found in the heart, trachea,
bladder and adult and fetal kidneys [5]. The only data on
PDGF-DD protein expression in human renal disease was
provided by Taneda et al., who investigated patients with
obstructive nephropathy and found PDGF-DD overexpres-
sion in the tubulointerstitum, co-localized with α-smooth
muscle actin-positive cells [15]. In another study, the same
group noted in normal adult human kidney the expression
of PDGF-DD protein in podocytes, vascular smooth muscle
cells and some neointimal cells of arteriosclerotic intrarenal
vessels [16]. Recently, PDGF-DD expression was found in
glomeruli but not in tubulointerstitium in kidney biopsies
from healthy subjects and patients with chronic allograft
nephropathy or acute vascular rejection. PDGF-DD expres-
sion was similar in all three groups examined [17]. However,
at least in our hands, the precise intrarenal localization of
PDGF-DD up-regulation has remained elusive, since exten-
sive attempts to immunostain PDGF-DD in human kidney
sections were not successful. Posttranscriptional regulation
of PDGF synthesis has not been described so far, and thus it
is unlikely that our RNA-based analysis might have missed
a major regulation of the intrarenal PDGF-DD mRNA syn-
thesis. On the other hand, renal posttranslational regulation
of PDGF-DD activity cannot be ruled out since PDGF-DD
is secreted as an inactive homodimer which needs prote-
olytical cleavage to become activated [5]. Our data thus
suggest that the source of the elevated PDGF-DD levels in
patients with IgAN resides outside the kidneys. This might
have implications for the pathogenesis of IgAN since the
extrarenal overexpression of PDGF-DD in mice induced a
pronounced proliferation of mesangial cells [3].
Another important observation of this study is that the
majority of patients (10 of 18) with lupus nephritis had de-
creased serum PDGF-DD levels. Of note, the only two lupus
patients with elevated serum PDGF-DD levels exhibited
class VI lupus nephritis. Glomerular and tubulointerstitial
mRNA expression did not differ from that of healthy living
donors, arguing for an extrarenal source of systemic PDGF-
DD down-regulation. Decreased PDGF-DD serum levels in
LN patients did not relate to leukopenia, as all enrolled
patients exhibited numbers within or above the normal
range (data not shown). Possibly low levels of PDGF-DD
in LN patients were related to immunosuppressive therapy,
since all LN patients received intensive immunosuppres-
sive treatment, whereas this was the case in only 18% of
IgAN patients and 30–42% of patients with other GNs.
The relevance of low serum PDGF levels in lupus remains
speculative. PDGF, including PDGF-DD, acts as a po-
tent chemoattractant for monocytes and macrophages [13].
In vitro, T cells stimulated with PDGF-BB produced in-
creased interleukin (IL)-2 and reduced IL-4, IL-5 and inter-
feron (IFN)-γ, suggesting that PDGF is a potent regulator of
T-cell function [18]. In line with this, imatinib mesylate, an
inhibitor of c-abl, PDGFR and c-kit protein tyrosin kinases,
was shown to inhibit dendritic cell differentiation and their
ability to activate proper T-cell responses in vitro [19]. In
a mouse model of lupus nephritis, imatinib treatment sig-
nificantly reduced mortality and renal injury [20]. Thus,
although some indications exist that PDGF may play an
important role in the regulation of the immune system, the
data are still inconclusive.
In summary, we present the first evidence for elevated
concentrations of circulating PDGF-DD levels in a sub-
set of adult patients with IgAN. Our data thereby further
support the rationale for anti-PDGF-DD therapy in mesan-
gioproliferative GN. Indeed, it has recently been shown in
a clinical phase I study that administration of a neutralizing
monoclonal antibody to PDGF-DD can reduce PDGF-DD
serum concentrations in normal persons to non-detectable
levels for prolonged periods [21]. We also provided the first
evidence that serum PDGF-DD levels are decreased in pa-
tients with LN. The role of such decrease remains elusive
and may be elucidated further in studies assessing PDGF-D
serum levels before and after induction therapy in LN.
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